# NEOPRISM-CRC (NCT05197322)

> NEOadjuvant PembRolizumab In Stratified Medicine - ColoRectal Cancer

No report yet. It can be ordered.

- Drugs tested: pembrolizumab
- Indication: high-risk stage 2 or 3 MMR-deficient colorectal cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05197322
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: University College, London
- Conditions: Adenocarcinoma of the Colon
- Interventions: Pembrolizumab; Pembrolizumab
- Enrollment: 88
- Primary outcome: Relapse-free survival

## Indexed commentary on NEOPRISM-CRC so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 21
- YouTube: 1
- Podcasts: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=neoprism-crc-nct05197322

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05197322", "email": "<work email>"}; the inbox owner confirms by the emailed link.